Prognostic signature based on hypoxia and RNA methylation regulatory genes can improve the prognostic and recurrence prediction ability of low-grade glioma.

A total of 18 drugs showed highly significant differences between risk groups based on GDSC1 and GDSC2 prediction analysis, there were 9 drugs (AZD5582, BMS-536924, Dasatinib, GSK269962A, IAP, MG-132, NU7441, PD0325901, rapamycin) with significantly lower IC50 in the high-risk group and 9 drugs (alisertib, AZD1208, BMS-754807, daporinad, doramapimod, linsitinib, navitoclax, SB505124, vorinostat) in the low-risk group.

also in 132,142 other papers